Novartis Stays Firm On India Plans After Gleevec: An Interview With India Vice Chairman Ranjit Shahani
This article was originally published in PharmAsia News
Novartis has been at the center of a long patent controversy, and although it recently faced an adverse ruling, India Vice Chairman Ranjit Shahani’s optimism about the Indian market is unshaken.
You may also be interested in...
MUMBAI - Swiss drug maker Novartis recently launched its ace anti-diabetes drug Galvus in India to take Merck's Januvia head on, but the company's larger focus seems to be shifting fast from the mega cities to the rural market where "real India lives.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.